science

Mavorixafor

Mavorixafor is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Mavorixafor rather than just read about it. In short: Mavorixafor, sold under the brand name Xolremdi, is a medication used for the treatment of WHIM syndrome. It is a CXC chemokine receptor 4 antagonist.

Key takeaways

Mavorixafor belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Mavorixafor to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Mavorixafor from memory before moving on to harder problems.

Reference excerpt

Mavorixafor, sold under the brand name Xolremdi, is a medication used for the treatment of WHIM syndrome. It is a CXC chemokine receptor 4 antagonist. It is taken by mouth. It was developed by X4 Pharmaceuticals. The most frequently reported adverse reactions include thrombocytopenia (low platelet counts), rash, rhinitis (stuffy nose), epistaxis (nosebleed), vomiting, and dizziness. Mavorixafor was approved for medical use in the United States in April 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical uses Mavorixafor is indicated in people twelve years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.

History The effectiveness of mavorixafor was evaluated in a 52-week, randomized, double-blind, placebo-controlled trial that enrolled 31 adolescents and adults with WHIM syndrome (NCT03995108). Mavorixafor improved absolute neutrophil counts and absolute lymphocyte counts, assessed over a 24-hour period four times throughout the study. Absolute neutrophil counts below 500 cells/μL and absolute lymphocyte counts below 1000 cells/μL are associated with an increased risk of infections. The average length of time over 24 hours that counts were above these levels was significantly longer with mavorixafor compared to the placebo group (15.0 hours compared to 2.8 hours for absolute neutrophil counts; 15.8 hours compared to 4.6 hours for absolute lymphocyte counts).

Society and culture

Names Mavorixafor is the international nonproprietary name.

Research Mavorixafor is in clinical trials for melanoma and renal cell carcinoma.

References

External links Clinical trial number NCT03995108 for "Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome" at ClinicalTrials.gov

Illustrations

Worked examples

Example 1 — a first encounter with Mavorixafor

Start with the simplest possible case. Write down what Mavorixafor claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Mavorixafor before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Mavorixafor ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Mavorixafor

In research: Mavorixafor appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Mavorixafor in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Mavorixafor is common in secondary-school and first-year university syllabi. It links to neighbouring topics Amines, Benzimidazoles, Tetrahydroquinolines, so understanding it makes those chapters shorter.
In everyday life: Look for Mavorixafor outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Mavorixafor in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Mavorixafor means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Mavorixafor out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Mavorixafor in simple terms?

Mavorixafor, sold under the brand name Xolremdi, is a medication used for the treatment of WHIM syndrome. It is a CXC chemokine receptor 4 antagonist.

Why does Mavorixafor matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Mavorixafor?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Mavorixafor.